ValueScore analyzes 10,000+ stocks so you don't have to. Get the top 5 picks — with the reasoning and the risks — in one short email every week. (fixed the double period; also "every week" instead of "every Monday" until Task 2 locks your send day — the sprint plan has you publishing Fridays)
No 40-stock watchlists, no market commentary, no filler. The five highest scores this week and why they earned them.
Every pick comes with what the score sees in the business and the one thing it can't see. You learn to read a score, not just follow one.
Does it make money? Is it healthy? Is the price fair? The score answers all three so you don't spend your Sunday in a 10-K.
Incyte (INCY) scores 81 out of 100. The score sees $5.1B in revenue anchored by one $3.5B drug, a shrinking share count from buybacks, and $98M of net insider buying in the last year including a $9.9M purchase by the CEO. It also flags the risk: 69% of revenue comes from a single product. That's the whole pick — the reason and the caveat — in four sentences.
Want five of these every week? Subscribe free →
Financial Health
Competitive Position
Management Quality
Valuation
Built ValueScore to do the fundamental analysis I kept putting off. Now sharing the five best scores every week.
Join 12,000 readers
Free. One email a week. (replace "Join 12,000 readers" — don't put a number here until it's one you're proud of)